Joint (JYNT) AI Stock Analysis

• Market Cap: $175.98M
• Dividend Yield: N/A
• Average Volume (3M): 64.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: -26.14%
• EPS Growth: 23.04%
• Country: US
• Employees: 443
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Care Facilities
• EPS (TTM): -0.03
• Shares Outstanding: 15,302,772
• 10 Day Avg. Volume: 67,835
• 30 Day Avg. Volume: 64,290
• PEG Ratio: -2.44
• Price to Book (P/B): 31.85
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 137.23
• Enterprise Value/Market Cap: 1.24
• Enterprise Value/Revenue: 0.67
• Enterprise Value/Gross Profit: 9.78
• Enterprise Value/Ebitda: 8.98
• 1Y Price Target: $15.50
• Price Target Upside: 35.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 56 Neutral
• Price Target: $12.00 ▲(5.08%Upside)

The Joint Corp. faces significant financial challenges, reflected in a low financial performance score due to ongoing net losses and declining equity. Technical analysis suggests a stable but neutral position. Valuation metrics are weak, given the negative P/E ratio. However, strategic initiatives highlighted in the earnings call and recent corporate events show potential for long-term improvement, partially offsetting immediate concerns.

Positive Factors

Digital Strategy

The Joint is advancing its digital strategy, with increased online scheduling capabilities and the launch of its first mobile app expected, which could improve the patient experience and drive repeat visits.

Financial Position

JYNT had $25.1M in cash and no debt, and it is expected to generate positive cash flows from continuing operations.

Profitability

The strategic shift is anticipated to result in The Joint becoming an overall more profitable business with an improved margin structure.

Negative Factors

Operational Uncertainty

The potential sale, relocation, or closure of company-owned clinics creates uncertainty.

Restructuring Risks

Execution risks remain, as the company has yet to finalize the sale of a significant number of corporate-owned clinics.

Joint Business Overview & Revenue Model

Company Description

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

How the Company Makes Money

The Joint Corp. generates revenue primarily through its network of company-owned and franchised chiropractic clinics. The company's revenue model includes membership fees, which provide patients with access to affordable chiropractic care on a regular basis, and walk-in visits from non-members. Additionally, franchise royalties and initial franchise fees contribute to its income streams. The Joint Corp. leverages its strong brand presence and operational model to expand its franchise network, thus increasing its market reach and revenue potential. The company's growth strategy includes expanding its clinic footprint and increasing consumer awareness of the benefits of chiropractic care.

Joint Financial Statement Overview

Summary

Joint faces challenges with profitability and cash flow sustainability despite maintaining reasonable margins and low leverage. The decline in revenue and equity over recent periods highlights potential financial instability, and consistent net losses are a significant concern for future growth.

Income Statement

The company has seen fluctuating revenue with a notable decline from 2023 to TTM (Trailing-Twelve-Months). Gross profit margin remains strong at approximately 63.5% for TTM. However, the consistent negative EBIT and net loss indicate ongoing operational challenges and profitability issues, as evidenced by negative net profit margins.

Balance Sheet

The balance sheet shows reasonable stability with a debt-to-equity ratio of about 0.11 in TTM, indicating low leverage. However, the decline in equity over the years and the low return on equity due to negative net income suggest potential financial stress. The equity ratio stands at 25.8%, showing moderate reliance on equity financing.

Cash Flow

Cash flow analysis shows positive operating cash flow, but decreasing over the periods. Free cash flow is positive but has been inconsistent, reflecting challenges in maintaining cash generation. The operating cash flow to net income ratio is negative due to consistent net losses, highlighting potential cash flow sustainability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.25M	51.90M	117.70M	101.91M	81.19M	58.68M
Gross Profit	22.38M	40.38M	107.15M	92.08M	72.68M	52.18M
EBITDA	3.87M	2.98M	9.14M	7.89M	12.16M	8.18M
Net Income	-8.68M	-8.53M	-9.75M	1.18M	7.57M	13.17M
Balance Sheet
Total Assets	77.19M	80.42M	87.15M	91.94M	84.04M	65.73M
Cash, Cash Equivalents and Short-Term Investments	21.92M	25.05M	18.15M	9.75M	19.53M	20.55M
Total Debt	2.25M	448.29K	16.73M	26.06M	22.45M	18.48M
Total Liabilities	57.26M	62.48M	62.38M	59.54M	54.48M	44.98M
Stockholders Equity	19.94M	17.92M	24.75M	32.37M	29.54M	20.75M
Cash Flow
Free Cash Flow	1.78M	8.23M	9.68M	2.31M	6.85M	6.99M
Operating Cash Flow	2.90M	9.42M	14.68M	11.08M	15.23M	11.18M
Investing Cash Flow	-578.01K	-631.55K	-6.19M	-20.78M	-14.14M	-4.60M
Financing Cash Flow	904.66K	-2.00M	174.12K	328.61K	-2.00M	5.60M

Joint Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JYNT, the sentiment is Neutral. The current price of 11.42 is below the 20-day moving average (MA) of 11.51, above the 50-day MA of 10.66, and above the 200-day MA of 11.09, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 51.64 is Neutral, neither overbought nor oversold. The STOCH value of 30.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JYNT.

Joint Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELMD	80 Outperform	$183.74M	27.16	16.56%	―	14.85%	64.96%
UTMD	79 Outperform	$187.75M	15.30	10.59%	2.16%	-19.92%	-16.22%
BTMD	67 Neutral	$158.54M	7.00	-7.92%	―	6.44%	322.20%
Sector *	65 Neutral	¥345.58B	10.59	-2.88%	2.65%	11.80%	-7.09%
ARAY	62 Neutral	$142.16M	233.90	1.48%	―	8.06%	―
JYNT	56 Neutral	$175.98M	―	-27.25%	―	-26.14%	23.04%
SGMO	47 Neutral	$142.82M	―	-262.12%	―	239.92%	79.41%

Joint Corporate Events

Joint Corp. Sells Clinics in Strategic Move

On June 23, 2025, The Joint Corp. entered into an Asset Purchase Agreement with Joint Ventures, LLC to sell 31 company-owned clinics in Arizona and New Mexico for $11.07 million. This transaction, expected to close by June 30, 2025, also involves acquiring regional developer rights in the Northwest Region, which includes 46 existing franchised clinics and 30 future development sites. Additionally, The Joint Corp. refranchised five clinics in Kansas and Missouri to Chiro 93, LLC. These strategic moves aim to enhance The Joint’s profitability and solidify its position as the largest pure play chiropractic care franchise system.

The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Corp. Appoints New CFO Scott J. Bowman

On June 10, 2025, The Joint Corp. announced the appointment of Scott J. Bowman as its new Chief Financial Officer, succeeding Jake Singleton. Bowman, who brings over 30 years of experience in finance, has previously served as CFO at several public companies, including Leslie’s, Inc. and Dave & Buster’s. His expertise in capital markets and strategic planning is expected to support The Joint Corp.’s strategy to reignite growth and improve profitability. The company aims to transform into a pure play franchisor and enhance its position as a leading health and wellness services provider in the U.S.

The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Corp. Appoints New Director and Chair

On June 3, 2025, The Joint Corp.’s Board of Directors expanded its size and appointed Sandi Karrmann as a new director, who will also serve as Chair of the Compensation Committee. Karrmann, with extensive experience in human resources and healthcare, is expected to contribute to the company’s strategic goals of enhancing talent and culture to boost growth and profitability. Additionally, the Board approved a stock repurchase plan to buy back up to $5 million of common stock by June 2027, aiming to optimize capital structure and enhance shareholder value.

The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Confirms Board Election and Key Approvals

On May 21, 2025, Joint company held its annual meeting of stockholders where several key decisions were made. The election of seven directors to the Board was confirmed, with each nominee receiving the necessary votes to serve until the next annual meeting in 2026. Additionally, the compensation of named executive officers was approved, and the appointment of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.

The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Corp. Reports Q1 2025 Financial Results

On May 8, 2025, The Joint Corp. reported its financial results for the first quarter of 2025, showing a 7% increase in revenue from continuing operations to $13.1 million compared to the same period in 2024. Despite a net loss from continuing operations of $506,000, the company demonstrated economic resilience with a 5% increase in system-wide sales to $132.6 million. The company is undergoing a transition to become a pure-play franchisor, implementing new marketing and operational strategies to enhance growth and profitability. The Joint Corp. expects system-wide sales to reach between $550 million and $570 million in 2025, with new franchised clinic openings projected between 30 and 40.